**Question:** A patient with Hodgkin's lymphoma is having a single cervical lymphnode. Biopsy showed lymphocyte predominant variant. Which of the following is the treatment of choice-

A. Chemotherapy
B. Radiotherapy
C. Hormone therapy
D. Immunotherapy

**Correct Answer:** **D. Immunotherapy**

**Core Concept:**
Hodgkin's lymphoma is a type of non-Hodgkin lymphoma that primarily affects the lymphatic system. The lymphocyte predominant variant is a subtype of Hodgkin's lymphoma characterized by a predominance of lymphocytes (T cells and B cells) in the tumor cells. The treatment options for Hodgkin's lymphoma are primarily based on the stage of the disease and the patient's overall health status.

**Why the Correct Answer is Right:**
Immunotherapy, specifically targeted therapies, is the treatment of choice for lymphocyte predominant Hodgkin's lymphoma due to the unique characteristics of this variant. Hodgkin's lymphoma cells have specific proteins (CD30) on their surface, making them susceptible to targeted therapies that inhibit these proteins.

**Why Each Wrong Option is Incorrect:**

A. Chemotherapy (Option A): Chemotherapy is a general term for the use of drugs to kill cancer cells. However, for lymphocyte predominant Hodgkin's lymphoma, targeted therapies are more effective and less toxic than conventional chemotherapy.

B. Radiotherapy (Option B): Radiotherapy uses ionizing radiation to damage cancer cells. While radiation therapy can be a part of treatment for Hodgkin's lymphoma, targeted therapies are more effective for lymphocyte predominant variant due to the presence of CD30 on tumor cells.

C. Hormone therapy (Option C): Hormone therapy is typically used to treat hormone-dependent tumors, not Hodgkin's lymphoma. Immunotherapy is more appropriate for this variant.

D. Immunotherapy (Option D): Immunotherapy is the correct treatment choice for lymphocyte predominant Hodgkin's lymphoma. In this case, targeted therapies like brentuximab vedotin or gemtuzumab ozogamicin are used to inhibit CD30 expression on tumor cells.

**Clinical Pearl:**
Targeted therapies have become a key component in the treatment of lymphocyte predominant Hodgkin's lymphoma due to their ability to specifically target CD30-expressing tumor cells, which are present in this variant. This increases the efficacy of treatment while reducing the toxicity compared to conventional chemotherapy.